Sponsor
Boehringer Ingelheim
54 PBAC submissions on file, active 2006–2025. 63% have been recommended.
Submissions
54
2006 → 2025
Win rate
63 %
34 recommended of 54 bucketable
Drugs
21 · 13 listed
unique molecules submitted
PBS spend captured
—
FY-latest govt benefit on owned drugs
Drug portfolio
Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.
Therapy area mix Respiratory 19 Endocrinology 13 Cardiovascular 6 Oncology 5 Neurology 5 Diabetes 3 Infectious disease 2 Other 1
Activity by year 2006 (2) · 2007 (2) · 2008 (2) · 2009 (2) · 2011 (4) · 2012 (2) · 2013 (4) · 2014 (2) · 2015 (9) · 2016 (5) · 2017 (6) · 2018 (2) · 2019 (1) · 2020 (2) · 2021 (2) · 2022 (1) · 2023 (1) · 2024 (4) · 2025 (1)
Rejection patterns
Across 14 Not recommended decisions on file.
1× Proposed population restriction to exon 19 deletion mutations not consistent with previous PBAC recommendations for all activating EGFR mutations1× inability to obtain special pricing arrangement (SPA) for afatinib1× PBAC did not accept that afatinib has unique characteristics compared to erlotinib and gefitinib1× exchangeability concerns regarding indirect comparisons between trials due to different chemotherapy regimens and baseline characteristics1× requested listing restriction to ECOG performance status 0–2 not supported by trial populations (LUX Lung 3 and 6 enrolled ECOG 0–1 only)Open on full dashboard →
Part of script.report — an independent tracker of every PBAC Public Summary Document and the PBS expenditure that follows. Built from public data on pbs.gov.au . Not affiliated with the Australian Department of Health, PBAC, or any pharmaceutical company.
script.report extracts information discussed in PBAC Public Summary Documents (PSDs), not independently calculated values. Where figures such as ICERs are shown, they reflect what was discussed or referenced in committee documentation — not confirmed inputs. For authoritative cost-effectiveness data, refer to the original PSD.